IONIS PHARMACEUTICALS INC (IONS) Stock Overview
NASDAQ:IONS - US4622221004 - Common Stock
IONS Key Statistics, Chart & Performance
The current stock price of IONS is 42.75 USD. In the past month the price decreased by -1.43%. In the past year, price decreased by -10.34%.
IONS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.65 | 367.55B | ||
| AMGN | AMGEN INC | 13.2 | 155.03B | ||
| GILD | GILEAD SCIENCES INC | 14.72 | 141.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.97 | 99.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.86 | 62.21B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.53B | ||
| ARGX | ARGENX SE - ADR | 76.37 | 43.33B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.06 | 35.68B | ||
| INSM | INSMED INC | N/A | 28.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.76B | ||
| NTRA | NATERA INC | N/A | 22.38B | ||
| BIIB | BIOGEN INC | 8.52 | 19.99B |
Related stock screener links
About IONS
Company Profile
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,069 full-time employees. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Company Info
IONIS PHARMACEUTICALS INC
2855 Gazelle Court
Carlsbad CALIFORNIA 92010 US
CEO: Brett P. MONIA
Employees: 1069
Phone: 17609319200
IONIS PHARMACEUTICALS INC / IONS FAQ
What is the stock price of IONIS PHARMACEUTICALS INC today?
The current stock price of IONS is 42.75 USD. The price increased by 1.38% in the last trading session.
What is the ticker symbol for IONIS PHARMACEUTICALS INC stock?
The exchange symbol of IONIS PHARMACEUTICALS INC is IONS and it is listed on the Nasdaq exchange.
On which exchange is IONS stock listed?
IONS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IONIS PHARMACEUTICALS INC stock?
33 analysts have analysed IONS and the average price target is 60.31 USD. This implies a price increase of 41.08% is expected in the next year compared to the current price of 42.75. Check the IONIS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IONIS PHARMACEUTICALS INC worth?
IONIS PHARMACEUTICALS INC (IONS) has a market capitalization of 6.81B USD. This makes IONS a Mid Cap stock.
How many employees does IONIS PHARMACEUTICALS INC have?
IONIS PHARMACEUTICALS INC (IONS) currently has 1069 employees.
What are the support and resistance levels for IONIS PHARMACEUTICALS INC (IONS) stock?
IONIS PHARMACEUTICALS INC (IONS) has a support level at 41.63 and a resistance level at 43.59. Check the full technical report for a detailed analysis of IONS support and resistance levels.
Is IONIS PHARMACEUTICALS INC (IONS) expected to grow?
The Revenue of IONIS PHARMACEUTICALS INC (IONS) is expected to grow by 38.9% in the next year. Check the estimates tab for more information on the IONS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IONIS PHARMACEUTICALS INC (IONS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IONS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IONS, evaluating the profitability, health, valuation and growth aspects
- IONIS PHARMACEUTICALS INC (IONS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IONIS PHARMACEUTICALS INC (IONS) Sales and EPS estimates to see what analysts future expectations are.
- IONIS PHARMACEUTICALS INC (IONS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IONIS PHARMACEUTICALS INC (IONS) Insider and Institutional Ownership to learn about the owners and their transactions.
- IONIS PHARMACEUTICALS INC (IONS) Stock Chart to make your own analysis
- IONIS PHARMACEUTICALS INC (IONS) Latest news and press-releases to stay up to date.
Does IONIS PHARMACEUTICALS INC (IONS) stock pay dividends?
IONS does not pay a dividend.
When does IONIS PHARMACEUTICALS INC (IONS) report earnings?
IONIS PHARMACEUTICALS INC (IONS) will report earnings on 2025-11-04, before the market open.
What is the Price/Earnings (PE) ratio of IONIS PHARMACEUTICALS INC (IONS)?
IONIS PHARMACEUTICALS INC (IONS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.84).
What is the Short Interest ratio of IONIS PHARMACEUTICALS INC (IONS) stock?
The outstanding short interest for IONIS PHARMACEUTICALS INC (IONS) is 7.46% of its float. Check the ownership tab for more information on the IONS short interest.
IONS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to IONS. When comparing the yearly performance of all stocks, IONS turns out to be only a medium performer in the overall market: it outperformed 61.61% of all stocks.
IONS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IONS. IONS may be in some trouble as it scores bad on both profitability and health.
IONS Financial Highlights
Over the last trailing twelve months IONS reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS increased by 26.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.99% | ||
| ROE | -42.46% | ||
| Debt/Equity | 0.99 |
IONS Forecast & Estimates
33 analysts have analysed IONS and the average price target is 60.31 USD. This implies a price increase of 41.08% is expected in the next year compared to the current price of 42.75.
For the next year, analysts expect an EPS growth of 15.47% and a revenue growth 38.9% for IONS